loading page

Resistance to daratumumab in patients with multiple myeloma
  • Katrine Fladeland Iversen
Katrine Fladeland Iversen
Syddansk Universitet

Corresponding Author:katrine.fladeland.iversen@rsyd.dk

Author Profile

Abstract

MM is an incurable cancer in the bone marrow. The treatment of MM has developed significantly during the last 20 years, which has resulted in increased survival. Daratumumab is the first CD38 antibody approved for treatment of MM. It has improved the treatment of MM even further. This is an evaluation of the modes of action of daratumumab and a description of the development of resistance with focus on inhibitory checkpoint receptors on CD8+ T-cells, complement activation and extracellular vesicles.
Submitted to Basic & Clinical Pharmacology & Toxicology
04 Mar 2024Editorial Decision: Revise Major
30 May 20241st Revision Received
31 May 2024Submission Checks Completed
31 May 2024Assigned to Editor
27 Jun 2024Editorial Decision: Accept